This review looked at how KRAS mutations affect the immune environment in patients with pancreatic, colorectal, and lung cancers. These mutations are very common in these types of tumors, appearing in 98% of pancreatic cases, 52% of colorectal cases, and 32% of lung cases. The study found that these mutations create a protective shield for the tumor by suppressing the immune system.
The research focused on how KRAS mutations lead to an environment where it is harder for the body's immune cells to fight the cancer. Specifically, these mutations can cause certain cells to promote tumor growth and hide the cancer from the immune system. This process involves several factors, including the expansion of specific suppressor cells and the increase of a protein called PD-L1.
Researchers also looked at two drugs, sotorasib and adagrasib, which are designed to block KRAS mutations. The review suggests that these targeted treatments might change the environment from one that protects the tumor to one that allows the immune system to work better. Because this is a review of current knowledge, it provides a reason for doctors to consider combining these drugs with other immunotherapies in the future.
